🔴 Nasus Pharma is trading 5.9% down today after yesterday’s CEO appointment rally

Nasus Pharma is trading 5.9% down today at $3.02 as the stock gives back a portion of its gains following a sharp rally on July 29.

• The previous surge was driven by the appointment of Brendan P. O'Grady, former CEO of Teva USA, as the new Chief Executive Officer of Nasus Pharma.
• No new company-specific news or analyst commentary has emerged today, suggesting the current downside is a result of profit-taking and typical post-news volatility.